Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9263296 | Diagnostic Microbiology and Infectious Disease | 2005 | 6 Pages |
Abstract
The activity of tigecycline (formerly GAR936), a novel glycylcycline, was tested against recent bloodstream infection (BSI) pathogen isolates from 6 continents. Frequency of clinical occurrence of these pathogens was determined and their antibiograms assessed using reference broth microdilution methods. A total of 26 474 strains were tested for tigecycline susceptibility according to the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) by the M7-A6 guidelines with interpretations from M100-S15 and the package insert. The rank order of pathogens was Staphylococcus aureus (33.1%), Escherichia coli (14.0%), coagulase-negative staphylococci (13.5%), Enterococcus spp. (12.3%), Klebsiella spp. (5.7%), Pseudomonas aeruginosa (4.2%), Enterobacter spp. (3.0%), β-hemolytic streptococci (2.9%), Streptococcus pneumoniae (2.3%), and viridans group streptococci (1.4%). Tigecycline exhibited a broader spectrum of activity against BSI isolates when compared to ciprofloxacin, tetracycline, aminoglycosides, and many β-lactams (imipenem). Tigecycline was highly active against most pathogens tested, including staphylococci (MIC90, 0.5 μg/mL), enterococci (MIC90, 0.25 μg/mL), streptococci (MIC90, â¤0.12 μg/mL), Escherichia coli (MIC90, 0.25 μg/mL), Klebsiella spp. (MIC90, 1 μg/mL), and Enterobacter spp. (MIC90, 2 μg/mL), but showed limited inhibition of Pseudomonas aeruginosa (MIC90, 16 μg/mL) and indole-positive or indole-negative Proteae (MIC90, 4-8 μg/mL). In summary, tigecycline exhibited a wide spectrum of antimicrobial potency versus BSI isolates collected worldwide. Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Helio S. Sader, Ronald N. Jones, Matthew G. Stilwell, Michael J. Dowzicky, Thomas R. Fritsche,